Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar ...

A gene therapy from Regeneron, a pancreatic cancer medicine from Revolution Medicines and a porphyria drug from Disc Medicine ...

Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive ...

Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to ...

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that ...

Bringing in a recruitment partner early gives sponsors the chance to test their protocols with real patients and gather ...

Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...

A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug ...

I-Mab is rebranding as a company that will form individual drugmaking subsidiaries. Elsewhere, Sanofi cut an immune drug deal and investors poured $140 million into a new hair loss treatment.

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...